Skip to main content

Table 4 Summary of the cohorts of gastrointestinal cytomegaloviral infection in immunocompetent patients (only the cohort with at least 10 patients)

From: Patient characteristics, clinical manifestations, prognosis, and factors associated with gastrointestinal cytomegalovirus infection in immunocompetent patients

 Ng 1999 (n = 10, colitis)Maiorana, 2003 (n = 11)Siciliano, 2014 (n = 14, ICU)Bernard, S 2015 (n = 13)Ko, 2015 (n = 51, colitis)Le 2017 (n = 42, colitis)Current study (n = 56)
Age717264.281 (54–88)65.2 ± 14.064.4 ± 19.473.0 ± 13.9
Male gender1 (10%)9 (88%)6 (42.8%)5 (38%)24 (47.1%)24 (57.1%)31 (55.4%)
Underlying disease
 Diabetes mellitus2 (20%) 5 (35.7%)3 (23.1%)15 (29.4%)15 (35.7%)20 (35.7%)
 Large vessel atherosclerotic diseases2 (20%)   11 (21.6%) (CVS dis)8 (19) CAD 8 (19) CVA21 (37.5%)
 Chronic kidney disease2 (20%) 7 (50%)2 (15.4%)16 (31.4%)6 (14.3%)13 (23.2%)
 Cirrhosis0 003 (5.9%)2 (4.8%)2 (3.6%)
 Cardiomyopathy  9 (64.2%)    
Status conditions at diagnosis
 Status       
• Outpatient     5 (11.9%)23 (41.1%)
• Inpatient     16 (38.1%)21 (37.5%)
• Intensive care unit  100% 11 (21.6%)21 (50%)12 (21.4%)
 Bacteremia     8 (19%)4 (7.1%)
 SIRS     28 (66.7%)29 (52.7%)
 Respiratory failure  71.4%  15 (35.7%)20 (35.7%)
 Inotropic drugs  78.5%  13 (31%)19 (33.9%)
 Acute renal failure     14 (33.3%)22 (39.3%)
Presentation
 Median presenting duration (days) (range)   8 (1–30)  1 (1–60)
 GI bleeding9 (90%) 10 (71.4%)6 (46.2%)30 (58.8%)22 (52.4%)40 (71.4%)
 Diarrhea8 (80%) 6 (42.8%)6 (46.2%)23 (45.1%)15 (35.7%)18 (32.1%)
 Abdominal pain0 1 (7.1%)08 (15.7%)12 (28.6%)9 (16.1%)
 Fever6 (60%) 2 (14.3%)4 (30.8%)8 (15.7%)17 (40.5%)27 (49.1%)
 Ileus  1 (7.1%)   4 (7.1%)
 Perforation0 0002 (4.8%)1 (1.8%)
 CMV at other organs0 00000 (0%)
CMV viremia
    CMV viral load (n = 4)Antigenemia (n = 30)pp65 Antigenemia (n = 18)CMV viral load (n = 27)
     Median, range
2 (0–11)
 Median, range 370 (0–85,599)
    Negative
3/4 (75%)
Negative
13 (43%)
Negative 8 (44.4%)Negative
11/27 (40.7%)
Treatment and outcomes
 Medications
• Ganciclovir3 (30%) 13 (92.8%)4 (30.8%)39 (76.5%)24 (57.1%)36/51 (70.6%)
• Valganclovir0  6 (46.2%) 12 (28.6%)3/51 (5.9%)
• Surgery1 (10%) 1 (7.2%)05 (9.8%)6 (14.3%)8/51 (15.7%)
• None7 (70%)  7 (53.8%) 12 (28.6%)13/51 (25.5%)
  Duration of treatment (week)   3233 (0–6)
  Improvement with no treatment7 (70%)   9 (17.6%) 4 (7.1%)
  Death in 6 months  10 (71.4%) (in hospital mortality)no CMV-related death7.8% (30 days)11 (26.2%) (in hospital mortality)20/51 (39.2%)